Abstract
In this pilot study, 22 women with breast cancer on tamoxifen therapy with at least two hot flashes a day took oral gabapentin at 300 mg three times a day for 4 weeks. The 16 women who completed the study had a mean decrease in hot flash duration of 73.6% (P = 0.027), frequency of 44.2% (P < 0.001), and severity of 52.6% (P < 0.001), with a complete response in 8/16 women. Side effects reported by four women who did not complete 4 weeks of the study were nausea (1/4), rash (1/4) and excessive sleepiness (3/4). Two additional patients did not provide complete data. Gabapentin is a promising new agent in the treatment of tamoxifen induced hot flashes, and should be studied further.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 87-89 |
| Number of pages | 3 |
| Journal | Breast cancer research and treatment |
| Volume | 83 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2004 |
Keywords
- Breast cancer
- Gabapentin
- Hot flashes
- Tamoxifen
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer'. Together they form a unique fingerprint.
Cite this
Pandya, K. J., Thummala, A. R., Griggs, J. J., Rosenblatt, J. D., Sahasrabudhe, D. M., Guttuso, T. J., Morrow, G. R., & Roscoe, J. A. (2004). Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast cancer research and treatment, 83(1), 87-89. https://doi.org/10.1023/B:BREA.0000010676.54597.22